(, NGL Fine-Chem Limited

Regd. Office 301, E — Square, Subhash Road, Vile Parle East, Mumbai 400057 Maharashtra, India.
Tel.: (+91 22) 40842222, Fax: (+91 22) 2610 8030, Email: [email protected] CIN’ L24110MH1981PLC025884, Website www.ngffinechem.com

August 1, 2025

To, To,
Listing Deparment Listing Department
BSE Limited National Stock Exchange of India Limited
Phiroze Jeejeebhoy Towers, Exchange Plaza, 5t Floor, Plot No.C/1, G Block,
Dalal Street, Fort, Bandra Kurla Complex, Bandra East,
Mumbai — 400 001. Mumbai 400050.
Scrip Code: 524774 Symbol: NGLFINE
Sub: Outcome of the Board Meeting Dated 1st August, 2025.

Dear Sir/Madam,

This is to inform you that the second Meeting of the Board of Directors of NGL Fine-Chem Limited
for the Financial Year 2025-2026 held on Friday, 15t August, 2025 at 301 E-Square, Subhash
Road, Vile Parle East, Mumbai 400057 approved the Unaudited Standalone & Consolidated
Financial Results for the quarter ended 30% June, 2025 pursuant to Regulation 33 of SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015 along with Limited Review
Report issued by the Statutory Auditors of the Company.

The aforesaid results are also being disseminated on Company's website at

www.nglfinechem.com.

The meeting of the Board of Directors commenced at 6.00 p.m. and concluded at 7.45 p.m.

Kindly take the same on your record.

Thanking you,

Yours faithfully,
For NGL Fine-Chem Limited

PALLAVI SATISH S rineian.

PEDNEKAR Dae 2020601 200118

Pallavi Pednekar
Company Secretary & Compliance Officer
Membership No: A33498
 NGL FINE-CHEM LIMITED
Regd Office: 301 E Square, Subhash Road, Vil Parle ( East), Mumbai 408357, Maharashira, India.
CIN: L24110MH1881PLCO25884
'UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2025 'UNAUDIT=D STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2025

s e S— S ]
Supa] ik 30062025 | 3oaz0zs | Sagezoad | sieszoas
T Revenus rom Operation o) v S683557 || T [Revenus rom Operaiens B T RT
1| other income 635.35 86304 || 1| other income 68534 @3.02) 62655 7584
W Total Revenue (14 11,05389 37,688.70 | [ _|Total Revenue (i+ih 1074115 s2273 543010 365051
W [Expenses W [Expenses:
a) Cost of Material Consumed 5,540.20 5,118.16 4,154.52 18,241.25 a) Cost of Material Cersumed 5,506.91 5,178.02 404243 18,379.74
b) (Increase)/Decrease in stock in trade and work in progress (351.02) (337.93) s6269 (©59) b) (Increase)Decreasesin stock in trade and work in progress (405.19) (285.95) ssras 13588
) Employee benefits expenses 157614 142474 119170 555461 <) Employee benefits expenses 144700 120827 108484 so7137
d) Finance Costs 12220 97.36 4434 233.41 d) Finance Costs. 12083 8469 a3 23074
‘) Depreciation and amortisation expenses 426.60 33204 30046 1,245.11 ) Depreciation and amortisation expenses 34468 28319 21404 92695
) Other expenses. 255582 266018 223140 854349 1 Other expenses. 275545 272454 245275 s7250
[ Total Expenses (IV) 9,869.94 9,294.57 8,485.11 34917.28 Total Expenses (V] 5,769.68 9,258.76 842994 34,516.96
V. [Profitloss) before exceptional items and tax (V) 118395 106.02 117870 277142 | V [Profit(ioss) before ex-eptionalitems and tax (V) 7147 03| 100018 230823
VI |Exceptional items - - - - VI_|Exceptional items - - - -
VIl |Profit/(loss) Before Tax (V-VI) 1,183.95 106.02 1,178.70 2,771.42 VII_|Profit/(loss) Before Taz V-VI) 7147 (36.03) 1,000.16 2,388.23
Vi |Tax Expense Vil [Tax Expense
la) Current Tax (130.00) (35.50)| (222.50)| (650.50)] 2) Current Tax (71.00) (182.50)| (560.00)|
Ib) Prior Years (0.88)] 25.42 - 27.80 b) Prior Years (088)| 2560 2580
o) Deffered Tax (128.01) (@1.57) (34.29) (36.30) ) Deffered Tax (135.18) “182) (35.09) (#053)
IX_[Profit (Loss) for the period from continuing operations (VI-Vil 52406 5436 92191 211243 ||_1X_|Profit (Loss) for the p=rod from continuing operations (VILVIl) 76441 (5209) 78257 181320
X |Other Comprehensive Income X |Other Comprehensive ncome
2. Gaini(Loss) on actuarial valuation of post employment benefr (@271) (1.62) 147 (s2:13) 2. Gain/(Loss) on actuasal valuation of post employment benefi{ (222) (179) 044 (5249)
b. Deferred tax on above 24 038 (030) 209 b. Deferred tax on above a1 043 (©a1) 87
. Other Comprehensive Income (Net of Tax) (24.47) (1.19) o087 (24.00) . Other Comprehensv= Income (Net of Tax) @a11) ) o33 (2430)
XI_|Total Comprehensive income 89959 5122 s2278 2,088.39 || X1_[Total Comprehensive in-ome 74030 (5339) 78230 178850
XIl_|Paid-up Equity Share Capital (Face Value of the Share Rs. /- eac| 308.90 308.90 308.90 308.90 |[ Xil [Paid-up Equity Share Capital (Face Value of the Share Rs. §/- eac 308.90 30850 30850 30850
o ::;:::.;fl::‘.: I:;\;:I::llon Reserve as per balance sheet A A N ars2a || o0 ;"f:;’:.‘:..i‘.‘éim v:;:l::uon Reserve as per balance sheet R - - s

XV |Earnings Per Share (EPS) X [Earnings Per Share (E°5)

) Basic v 146 | oss e 1as2 e 3419 2) Basic z 37|t asmft ner|r 23
o) Dituted 3 1as6| v oss | 1as2 e 3419 b) Diluted z 237 omlr uer|e 235

1 The above results were reviewed by Audit Committee and approved by the Board of Directors at their meeting held on Friday, st 1 The above results were seviewed by Audit Comittee and approved by the Board of Directors at their mesting
held on Friday, 1st
August 2025. These results were subjected to Limited Review by the Statutory Auditors of the Company. August 2025. These resuits were subjected to Limited Review by the Statutory Aucitors of the Company.
2 The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules 2015 2 The above financial res:sts have been prepared in accordance
with the Companies (Indian Accounting Standards) Rules 2015
(IndAS prescribed under Section 133 of the Companies Act 2013 and read with the rules framed thereunder) and Regulation 33 of (IndAS prescribed under<Section 133 of the Companies Act 2013 and read with the rules framed thereunder)
and Regulation 33 of
SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended from time to time SEBI (Listing Obligatio=s and Disclosure Requirements) Regulations 2015, 2s amended from time
to time
3 The Company i of the view that it manufactures pharmaceuticals, which is a single business segment in accordance with IND-AS 3 The Company is of tne vw that it manufactures pharmaceuticals, which is a single business segment in accordance with IND-AS
108 "Operating Segment” notified pursuant to Companies (Indian Accounting Standards) Rule 2015. 108 “Operating Segment- notified pursuantto Companies (Indian Accounting Standards) Rule 2015.
4 The consolidated results are for NGL Fine Chem Limited together with its 100% subsidiary Macrotech Polychem Private Limited. 4 Previous period figures Fave been regroupedirearranged wherever necessary.
& The figures forthe quarter ended March 31, 2025 are the balancing igures between the audited figures in respect o the full year 5 The figures for the quarcer ended March 31, 2025 are the balanci
ended March 31, 2025 and the published yearto date figures upto the the third quarter ended December 31, 2024
of the relevant ended March 31, 2025 i the published year
to date figures.
financial year financial year /
6 Previous period figures have been regroupedirearranged wherever necessary.

: Mumbai
Date: August1,2025
 MANEK & ASSOCIATES .,B e camaneoom
ima
[email protected]
IND 1A CHARTERED ACCOUNTANTS
102, 1st Floor, 47 Avenue, Prarthana Samaj Road, Vile Parle (East), Mumbai - 400 057.

SHAILESHMANEK MITTUL B. DALAL

B.Com. (Hor3s),Grad. CW.A,, F.C.A. B.Com.F.CA
Cell : 491 93 22226311 Coll : +91 80973 74277

Independent Auditor’s Review Report on Unaudited Quarterly Financial Results of the

Company Pursnant to the Regnlation 33 of the SEBI (Listing Obligations And Disclosure
Requirements) Regulations, 2015 (as amended)

Review report W
The Board of Directors,
M/S.NGL Fine-Chem Limited

1. We have reviewed the accompanying statement of Unaudited Financial results of

M/S.NGL Fine-Chem Limited (“the Company™) for the quarter ended June 30, 2025,
attached herewith, being submitted by the Company pursuant to the requirement of
Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirement)
Regulation, 2015, as amended ( the “ Listing Regulations”).

2. This statement, which is the responsibility of the Company’s Management and

approved by the Board of Directors and has been prepared in accordance with the
recognition and measurement principles laid down in the Indian Accounting Standard
34, (“IND AS 34") “ Interim Financial Reporting” prescribed under Section 133 of the
Companies Act, 2013 as amended read with relevant rules issued thereunder and other
accounting principles generally accepted in India. Our responsibility is to issue a report
on these financial statements based on our review.

3. We conducted our review of the Statement in accordance with the Standard on

Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed
by the Independent Auditor of the Entity”, issued by the Institute of Chartered
Accountants of India. This standard requires that we plan and perform the review to
obtain moderate assurance as to whether the financial statements are free of material
misstatement. A review is limited primarily to inquiries of company personnel and
analytical procedures applied to financial data and thus provides less assurance than an
audit. We have not performed an audit and accordingly, we do not express an audit
opinion.
 MANEK & ASSOCIATES

4. Based on our review conducted as above, nothing has come to our attention that
causes us to believe that the accompanying Statement of Unaudited Financial results
prepared in accordance with recognition and measurement principles laid down in the
aforesaid Indian Accounting Standard (“IND AS”) specified under Section 133 of the
Companies Act, 2013, as amended, read with relevant rules issued thereunder and other
recognized accounting principles generally accepted in India, has not disclosed the
information required to be disclosed in terms of Regulation 33 of the SEBI (Listing
Obligations and Disclosure Requirements) Regulations, 2015, including the manner in
which, it is to be disclosed, or that it contains any material misstatement.

For MANEK AND ASSOCIATES

Chartered Accountants
Firm’s Registration No.:126679W

o
e
(MITTUL DALAL)
MUMBAI Partner
Dated:1st August, 2025 Membership Number:172676
UDIN: 25172676BMJLPB6477

‘Y:\Data\FY 2019-2020 and other previous years\NGL\Limited review\LIMITED REVIEW JUNE 2025\NGL- C1-Limited review
 CAc| MANEK & ASSOCIATES .., e s
INDIA CHARTERED ACCOUNTANTS [email protected]
camanek.com
102, 1st Floor, 47 Avenue, Prarthana Samaj Road, Vile Parle (East), Mumbai - 400 057.

SHAILESH MANEK
B.Com. (Hors), Grad. C.W.A., F.C.A.
MITTUL B. DALAL
B.Com.F.C.A.
Cell : +91 93222 26311
Cell : +91 80973 74277

Independent Auditor’s Review Report on the unandited quarter ended conenlidated

linanclal results of M/S. NGL Fine-Chem Limited Pursuant to
the Regulation 33 of the
SEBI (Listing Obligations and Disclosure Requirements) Regulations,
2015
To,
The Board of Directors,
M/S. NGL Fine-Chem Limited

1. We have reviewed the accompanying Statement of Consol

idated Unaudited
Financial Results of M/S. NGL Fine-Chem Limited (“the
Parent”) and its
subsidiary M/S. Macrotech Polychem Private Limited
(the Parent and its
subsidiary together referred to as “the Group”, and its share of the
net profit/loss)
after tax and total comprehensive income/loss of its associates
and joint ventures
for the quarter ended June 30, 2025 and for the period from
01t April 2025 to
30t June 2025 (“the Statement”), being submitted by the
Parent pursuant to the
requirement of Regulation 33 of the SEBI (Listing Obliga
tions and Disclosure
Requirements) Regulations, 2015, as amended.

2. This Statement, which is the responsibility of the Parent

's Management and
approved by the Parent’s Board of Directors and has been prepar
ed in accordance
with the recognition and measurement principles laid down
in Indian Accounting
Standard 34 “Interim Financial Reporting” (“Ind AS 34”),
prescribed under Section
133 of the Companies Act, 2013, and other accounting principles generally
accepted in India. Our responsibility is to express a conclu
sion on the Statement
based on our review.

3. We conducted our review of the Statement in accordance with

the Standard on
Review Engagements (SRE) 2410 “Review of Interim Financial Information
Performed by the Independent Auditor of the Entity”, issued
by the Institute of
Chartered Accountants of India. A review of interim financial information
consists of making inquiries, primarily of persons respon
sible for financial and
accounting matters, and applying analytical and other
review procedures. A
review is substantially less in scope than an audit conducted
in accordance with
Standards on Auditing and consequently does not enable
us to obtain assurance
that we would become aware of all significant matters
that might be identified in
an audit. Accordingly, we do not express an audit opinion.
 MANEK & ASSOCIATES

We also performed procedures in accordance with the circular issued by the SEBI
under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the result of M/S. Macrotech Polychem Private Limited,
its wholly owned subsidiary.

Based on our review conducted and procedures performed as stated in paragraph

3 above nothing has come to our attention that causes us to believe that the
accompanying Statement, prepared in accordance with the recognition and
measurement principles laid down in the aforesaid Indian Accounting Standard
and other accounting principles generally accepted in India, has not disclosed the
information required to be disclosed in terms of Regulation 33 of the SEBI (Listing
Obligations and Disclosure Requirements) Regulations, 2015, as amended,
including the manner in which itis to be disclosed, or that It contains any material
misstatement.

For MANEK & ASSOCIATES

Chartered Accountants
Firm’s Registration No.:126679W

o
(MITTUL DALAL)
MUMBAI Partner
Dated : 15t August, 2025 Membership Number:172676
UDIN: 25172676BMJLPC2007

Y:\Data\FY 2019-2020 and other previous years\NGL\Limited review\LIMITED REVIEW JUNE 2025\NGL-C3-Conso-Limited Review(1)